Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.28
Price+0.83%
$0.06
1Y
Price
Market Cap
$419.922m
Small
Price/Earnings 3y Avg5y Avg
20.8x
Premium
Premium
Financials Overview
Key metrics over the past few years+22.0%
EBITDA Margin+11.3%
Net Profit Margin+14.5%
Free Cash Flow MarginRevenue
$174.787m
+8.6%
1y CAGR+10.6%
3y CAGR+14.1%
5y CAGREarnings
$20.444m
+41.4%
1y CAGR+191.0%
3y CAGR+142.2%
5y CAGREPS
$0.36
+44.0%
1y CAGR+170.2%
3y CAGR+127.7%
5y CAGRBook Value
$265.232m
$377.210m
Assets$111.978m
Liabilities$11.470m
DebtDebt to Assets
3.0%
0.3x
Debt to EBITDAFree Cash Flow
$18.327m
-50.3%
1y CAGR+781.5%
3y CAGR+658.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company